<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056025</url>
  </required_header>
  <id_info>
    <org_study_id>2020/79-MIN-HUGC</org_study_id>
    <nct_id>NCT05056025</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.</brief_title>
  <acronym>REVERS</acronym>
  <official_title>A PILOT STUDY TO EVALUATE THE PROGRESSION OF THE DISEASE AND RESPONSE TO SUPPLEMENTATION WITH POSTBIOTICS IGEN-0222 IN PATIENTS WITH MACULAR DEGENERATION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de la Macula y la Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Igen BioLab SLU</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de la Macula y la Retina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to establish the efficacy and safety of supplementation with postbiotics in&#xD;
      patients with macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>12 months</time_frame>
    <description>Median change difference in the % reduced threshold in microperimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Color vision change</measure>
    <time_frame>12 months</time_frame>
    <description>Median change in red/green and yellow/blue color thresholds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Threshold microperimetry</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change of Average Threshold microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean Change of Best corrected visual acuity (BCVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low luminance visual acuity (LLVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean Change of Low luminance visual acuity (LLVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rod and cone sensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change of Rod and cone sensitivity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced Vision and Optometric Test (AVOT)</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change AVOT vision test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) conversion loci</measure>
    <time_frame>12 months</time_frame>
    <description>Number of scans within the optical coherence tomography OCT cube as as per protocol (Spectralis OCT cube protocol: 20º x 20ª, 97b-scan, high-resolution, 62 microns between scans centered at the fovea) with features of iRORA2 conversion loci (change from baseline to 12 months of iRORA loci).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete retinal pigment epithelial and outer retinal atrophy (cRORA) conversion loci</measure>
    <time_frame>12 months</time_frame>
    <description>Number of scans within the OCT cube as as per protocol with of features of cRORA (change from baseline to 12 months of cRORA loci).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of cumulative cRORA conversion</measure>
    <time_frame>12 months</time_frame>
    <description>Area of cumulative cRORA conversion as measured in mm2 by en face OCT projection scans of the OCT cube as as per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperreflective dots(HRD)+ (retinal pigment epithelium)RPE defects areas conversion</measure>
    <time_frame>12 months</time_frame>
    <description>Number of scans within the OCT cube as as per protocol with HRD+RPE defects areas conversion (change from baseline to 12 months of HRD+RPE defects)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in outer nuclear layer (ONL) volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in outer nuclear layer (ONL) volume measured by the spectralis software after manually correction of the layer segmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of drusen &gt; 100 microns height</measure>
    <time_frame>12 months</time_frame>
    <description>Change of number of drusen of &gt; 100 microns height measured by OCT within the OCT cube as as per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of subretinal drusenoid deposits (SDD) through ellipsoid zone (ELZ)</measure>
    <time_frame>12 months</time_frame>
    <description>Change of number of subretinal drusenoid deposits (SDD) through ellipsoid zone within the OCT cube as as per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of SDD ribbon</measure>
    <time_frame>12 months</time_frame>
    <description>Change of number SDD ribbon within the OCT cube as as per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to choroidal neovascularization (CNV)</measure>
    <time_frame>12 months</time_frame>
    <description>Any conversion to any type of macular neovascularization (MNV) within the OCT cube as as per protocol 1 as per OCT features of leakage, and/or intrarretinal, subretinal or subRPE fluid, and/or presence of Subretinal hyperreflective material(SHRM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>AMD</condition>
  <condition>Soft Drusen</condition>
  <condition>Reticular Pseudodrusen</condition>
  <condition>Drusen Stage Macular Degeneration</condition>
  <condition>Drusen (Degenerative) of Macula, Bilateral</condition>
  <arm_group>
    <arm_group_label>postbiotics with vitamins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamins</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vitamins (AREDS formulation and recommended daily dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Postbotics and Vitamins</intervention_name>
    <description>2 capsule 3 times a day, before meals</description>
    <arm_group_label>postbiotics with vitamins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamins</intervention_name>
    <description>2 capsule 3 times a day, before meals</description>
    <arm_group_label>vitamins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of either gender aged 50 years or older with high risk intermediate AMD&#xD;
             defined as the following criteria:&#xD;
&#xD;
        &gt;4 areas of at least iRORA or iORA (incomplete RPE and outer retinal atrophy and incomplete&#xD;
        outer retinal atrophy).&#xD;
&#xD;
        1 area of cRORA + 2 &gt; areas of iRORA. &lt; 1 mm2 of cRORA (complete RPE and outer retinal&#xD;
        atrophy). No exudative neovascular AMD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Best corrected visual acuity in the study eye less than 20/400 by ETDRS. Not ability to&#xD;
        provide written informed consent. Not ability to return for all trial visits. if subject&#xD;
        cannot attend all trial required visits. GA secondary to any condition other than&#xD;
        specified. Any ocular condition in the study eye that would progress during the study that&#xD;
        could affect central vision or otherwise be a confounding factor.&#xD;
&#xD;
        Concomitant treatment with any ocular or systemic medication that is known to be toxic to&#xD;
        the lens, retina or optic nerve. Anti -VEGF therapy is allowed in Cohort B.&#xD;
&#xD;
        Presence of intraocular inflammation (≥ trace cell or flare), macular hole, pathologic&#xD;
        myopia, epiretinal membrane, evidence of significant vitreo-retinal traction maculopathy,&#xD;
        vitreous hemorrhage or aphakia (pseudophakia with or without an intact capsule is not an&#xD;
        exclusion criteria).&#xD;
&#xD;
        Presence of idiopathic or autoimmune-associated uveitis in either eye. Significant media&#xD;
        opacities, including cataract, which might interfere with visual acuity, assessment of&#xD;
        toxicity, fundus photography or fundus autofluorescence. Subjects should not be entered if&#xD;
        there is likelihood that they will require cataract surgery in the study eye in the&#xD;
        following year.&#xD;
&#xD;
        Any intraocular surgery or thermal laser within three (3) months of trial entry.&#xD;
&#xD;
        Any prior thermal laser in the macular region, regardless of indication. History of any of&#xD;
        the following procedures: Posterior vitrectomy, filtering surgery (e.g. trabeculectomy),&#xD;
        glaucoma drainage device, corneal transplant or retinal detachment.&#xD;
&#xD;
        Previous therapeutic radiation in the region of the study eye. Any treatment with an&#xD;
        investigational agent in the past 60 days for any condition.&#xD;
&#xD;
        Pregnant or nursing women. Additionally, women with childbearing potential must be using at&#xD;
        least two effective contraception methods.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Mones, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de la Macula</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Mones, MD PhD</last_name>
    <phone>+34 935 950 155</phone>
    <email>jmones@institutmacula.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miriam Garcia, OD, MSc</last_name>
    <phone>+34 935 950 155</phone>
    <email>mgarcia@institutmacula.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de la Macula</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi M Mones, MD, PhD</last_name>
      <phone>+34935950155</phone>
      <email>jmones@institutmacula.com</email>
    </contact>
    <contact_backup>
      <last_name>Marc Biarnes, OD, PhD</last_name>
      <phone>+34935950155</phone>
      <email>mbiarnes@institutmacula.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi M Mones, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de la Macula y la Retina</investigator_affiliation>
    <investigator_full_name>Jordi Mones MD PhD</investigator_full_name>
    <investigator_title>Jordi Mones MD, PhD</investigator_title>
  </responsible_party>
  <keyword>postbiotic</keyword>
  <keyword>vitamins</keyword>
  <keyword>drusen</keyword>
  <keyword>intermediate AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Drusen</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

